Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Trial ID #	NCT03486301
Phase	I
Drug Class	Immunotherapy: Immune Cell Stimulators/TLR7/8
Drug Name	BDB001
Drugs in Trial	BDB001, Pembrolizumab
Eligible Participant	Advanced solid tumors
Reference	Patel MR et al. BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results. J Clin Oncol (2021) 39 (suppl 15; abstr 2512) https://meetinglibrary.asco.org/record/196042/abstract Patel MR et al. Poster https://www.clearityfoundation.org/wp-content/uploads/2021/06/BDB001-poster-ASCO-2021-scaled.jpeg